<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0015">
 <label>15.</label>
 <mixed-citation publication-type="journal">
  <string-name>
   <surname>Lawitz</surname>
   <given-names>E</given-names>
  </string-name>, 
  <string-name>
   <surname>Gane</surname>
   <given-names>E</given-names>
  </string-name>, 
  <string-name>
   <surname>Pearlman</surname>
   <given-names>B</given-names>
  </string-name>, et al. 
  <article-title>Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label Phase 2 trial</article-title>. 
  <source>
   <italic toggle="yes">Lancet (London, England)</italic>
  </source>. 
  <year>2015</year>;
  <volume>385</volume>(
  <issue>9973</issue>):
  <fpage>1075</fpage>â€“
  <lpage>1086</lpage>. doi:
  <pub-id pub-id-type="doi">10.1016/S0140-6736(14)61795-5</pub-id>
 </mixed-citation>
</ref>
